《盈警響號》金斯瑞生物科技(01548.HK)料中期虧損擴大至最多1.77億美元
金斯瑞生物科技(01548.HK)發盈警,料中期將錄得1.53億美元至1.77億美元虧損,較去年同期之3,330萬美元擴大。
公司表示,除傳奇生物科技以外,公司非細胞療法業務的利潤料約為1,610萬美元至1,880萬美元。對傳奇的投資、即細胞療法業務之持續運營料將錄得8,900萬美至1.03億美元虧損,其中不計入包括發行A類可轉換可贖回優先股的佣金、有關優先股的公允價值變動,及上市費用造成的一次性費用。虧損中包括研發費用9,650萬美元至1.12億美元。另外,期內因A類可轉換可贖回優先股公允價值變動導致8,000萬美元之一次性非現金費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.